Tachyum Prodigy Complete Software Package Enters Testing
LAS VEGAS–(BUSINESS WIRE)–#Linux—Tachyum® today announced that it has completed development of the software stack for…
LAS VEGAS–(BUSINESS WIRE)–#Linux—Tachyum® today announced that it has completed development of the software stack for…
InsightAI harnesses the power of Generative AI to help ISN customers discover insights from large…
LONG BEACH, Calif.–(BUSINESS WIRE)–#Laserfiche–New research by Medical Group Management Association (MGMA) and Laserfiche — the…
New authorization solution enables clients to personalize their cardholder experiences and improve profitability for qualified…
PRESS RELEASE AB SCIENCE WILL HOST A LIVE WEBCAST ON THE MASITINIB DEVELOPMENT PROGRAM IN…
Mithra to hold five presentations on key role of estrogens in women’s health, including Estetrol…
– Final overall survival analysis of the JUPITER-02 trial shows first-line treatment with LOQTORZI plus…
VANCOUVER, British Columbia, Nov. 28, 2023 (GLOBE NEWSWIRE) — Derm-Biome Pharmaceuticals Inc, a Vancouver based…
PALO ALTO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex”…
Decreases workforce by approximately 50% and reduces commercial manufacturing expenses to prioritize spend towards topline…
CAMPBELL, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) — VIVUS LLC, a biopharmaceutical company committed to…
TEL AVIV, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or…
SEATTLE, Nov. 28, 2023 (GLOBE NEWSWIRE) — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company…
BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) — Cerevance, a company focused on developing novel precision…
SAN CARLOS, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine…
Proof of Concept – Evaxion’s AI-Immunology™ platform demonstrates success in designing precision cancer vaccines in…
The pre- clinical trial conducted using the combined treatment of SciSparc’s proprietary CannAmide™ and Clearmind…
Results from pre- clinical trial indicate potential effect in various metabolic parameters including fat oxidation,…
Cohort 9 Following completion of the 21-day observation period at 3.4 mg/kg (Cohort 9), no…
Now seeking out license opportunities for SYMJEPI® SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) —…